Top

American Journal of Cardiovascular Drugs

Published in:

Open Access 01-10-2017 | Review Article

The Real Role of β-Blockers in Daily Cardiovascular Therapy

Authors: Csaba András Dézsi, Veronika Szentes

Published in: American Journal of Cardiovascular Drugs | Issue 5/2017

Abstract

The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been subject to diverse trends and changes over the decades. With the advent of a wide variety of excellent drugs for the treatment of antihypertension, β-blockers have been relegated from the first-line treatment of essential hypertension. However, they remain the drugs of first choice in recommendations from the respective medical societies for heart failure, coronary artery disease, and atrial fibrillation as well as in hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. When indicated, cardioselective β-blockers should be prescribed in patients with diabetes mellitus or chronic obstructive pulmonary disease. We review the available evidence for the use of β-blockers in clinical conditions in which recommendations can be made for everyday practice.

Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics—2010 update. A Report From the American Heart Association. Circulation. 2010;121:e1–170.CrossRef

Taylor J, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34(28):2108–9.PubMed

Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;11:CD002003.PubMed

Bui AL, Horwich TB, Fonarow GC, et al. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.PubMedCrossRef

Gheorghiade M, Colucci WS, Swedberg K. β-Blockers in chronic heart failure. Circulation. 2003;107:1570–5.PubMedCrossRef

Wilcox CS, Tisher CC. Handbook of nephrology and hypertension. Philadelphia: Lippincott Williams & Wilkins; 2008.

Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55.PubMedPubMedCentralCrossRef

Doughty RN, MacMahon S, Sharpe N, et al. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23(3):814–21.PubMedCrossRef

Lechat P, Packer M, Chalon S, et al. Beta-blockers in heart failure: meta-analysis of randomized trials. Circulation. 1998;98:1184–91.PubMedCrossRef

10.

Marazzi G, Volterrani M, Caminiti G, et al. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. J Cardiac Fail. 2011;17(9):703–9.CrossRef

11.

Nodari S, Metra M, Dei Cas L. β-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621–7.PubMedCrossRef

12.

McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef

13.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.PubMedCrossRef

14.

Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–906.PubMedCrossRef

15.

CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.CrossRef

16.

Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.PubMedCrossRef

17.

Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295–302.PubMedCrossRef

18.

Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–25.PubMedCrossRef

19.

Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J. 1997;18:560–5.PubMedCrossRef

20.

Heidenrich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27–34.CrossRef

21.

Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13.PubMedCrossRef

22.

Lin TY, Chen CY, Huang YB. Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients. Int J Cardiol. 2017;230:378–83.PubMedCrossRef

23.

Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–16.PubMedCrossRef

24.

Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147(2):324–30.PubMedCrossRef

25.

Böhm M, Link A, Cai D, et al. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med. 2011;39(5):940–4.PubMedCrossRef

26.

Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin Pharmacol Ther. 2014;95(3):281–93.PubMedCrossRef

27.

Yamamoto K, Origasa H, Hori M, et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15(1):110–8.PubMedCrossRef

28.

van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150–8.PubMedCrossRef

29.

Bavishi C, Chatterjee S, Ather S, et al. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015;20:193–201.PubMedCrossRef

30.

Liu F, Chen Y, Feng X, et al. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One. 2014;9(3):e90555.PubMedPubMedCentralCrossRef

31.

Zhou J, Shi H, Zhang J, et al. Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail. 2010;12(2):181–5.PubMedCrossRef

32.

Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease. A systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:1152–61.PubMedCrossRef

33.

Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease a meta-analysis of randomized trials. Circ Heart Fail. 2011;4:18–26.PubMedCrossRef

34.

Castagno D, Jhund PS, McMurray JJ, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail. 2010;12:607–16.PubMedCrossRef

35.

Barsness GW, Holmes DR Jr, editors. Coronary Artery Disease: New Approaches without Traditional Revascularization. London: Springer; 2011.

36.

Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J. 1993;14 Suppl F:18–25.

37.

Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease. A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65:1372–407.PubMedCrossRef

38.

Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.PubMedCrossRef

39.

de Vries RJ, van den Heuvel AF, Lok DJ, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The NetherlandsWorking Group on Cardiovascular Research (WCN). Int J Cardiol. 1996;57:143–50.PubMedCrossRef

40.

Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96–103.PubMedCrossRef

41.

van de Ven LL, Vermeulen A, Tans JG, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol. 1995;47:217–23.PubMedCrossRef

42.

Bangalore S, Bhatt DL, Steg PG, et al. β-Blockers and cardiovascular events in patients with and without myocardial infarction. Post hoc analysis from the CHARISMA Trial. Circ Cardiovasc Qual Outcomes. 2014;7:872–81.PubMedCrossRef

43.

Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015;386:691–701.PubMedCrossRef

44.

Huang HL, Fox KA. The impact of beta-blockers on mortality in stable angina: a meta-analysis. Scott Med J. 2012;57(2):69–75.PubMedCrossRef

45.

β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707–14.CrossRef

46.

Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67(6 Pt 2):I26–32.PubMed

47.

The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801–7.CrossRef

48.

First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2(8498):57–66.

49.

Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71.PubMedCrossRef

50.

Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intravenous beta-blockers in patients with acute coronary syndrome—a meta-analysis of randomized trials. Int J Cardiol. 2013;168(2):915–21.PubMedCrossRef

51.

Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83(2):422–37.PubMedCrossRef

52.

Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo controlled trial. Lancet. 2005;366:1622–32.PubMedCrossRef

53.

Dargie HJ, et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.PubMedCrossRef

54.

Ambrosio G, Flather MD, Böhm M, et al. β-Blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart. 2011;97:209–14.PubMedCrossRef

55.

Ellison KE, Hafley GE, Hickey K, et al. Effect of β-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation. 2002;106:2694–9.PubMedCrossRef

56.

Misumida N, Harjai K, Kernis S, et al. Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A meta-analysis. J Cardiovasc Pharmacol Ther. 2016;21(3):280–5.PubMedCrossRef

57.

Schoonderwoerd BA, Smit MD, Pen L, et al. New risk factors for atrial fibrillation: causes of ‘not-so-lone atrial fibrillation’. Europace. 2008;10(6):668–73.PubMedCrossRef

58.

Gussak I, Antzelevitch C, Wilde AAM, et al., editors. Electrical diseases of the heart: genetics, mechanisms, treatment, prevention. London: Springer; 2013.

59.

Camm AJ, Lip GY, De Caterina R, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.PubMedCrossRef

60.

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.PubMedCrossRef

61.

Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201–8.PubMedCrossRef

62.

Chao T, Liu C, Tuan C, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132:1604–12.PubMedCrossRef

63.

Piccini JP, Allen LA. Heart failure complicated by atrial fibrillation. Don’t bury the beta-blockers just yet. JACC Heart Fail. 2017.

64.

Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013;15:324–33.PubMedCrossRef

65.

Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart Fail. 2017.

66.

Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction. Findings from the Swedish Heart Failure Registry. Circ Heart Fail. 2015;8(5):871–9.PubMedCrossRef

67.

Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103(10):1428–33.PubMedCrossRef

68.

Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235–43.PubMedCrossRef

69.

University of Birmingham. Rate control therapy evaluation in permanent atrial fibrillation (RATE-AF) [ClinicalTrials.gov identifier NCT02391337]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02391337.

70.

Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000;36(1):139–46.PubMedCrossRef

71.

van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure: experiences from the MERIT-HF Study. Eur J Heart Fail. 2006;8(5):539–46.PubMedCrossRef

72.

Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28(4):457–62.PubMedCrossRef

73.

Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26(13):1303–8.PubMedCrossRef

74.

McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4):525–30.PubMedCrossRef

75.

Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery (review). Cochrane Database Syst Rev. 2013;1:003611.

76.

Burgess DC, Kilborn MJ, Keech AC, et al. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J. 2006;27(23):2846–57.PubMedCrossRef

77.

Sakamoto A, Hamasaki T, Kitakaze M, et al. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Adv Ther. 2014;31(4):440–50.PubMedPubMedCentralCrossRef

78.

Wang HS, Wang ZW, Yin ZT, et al. Carvedilol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. PLoS One. 2014;9(4):e94005.PubMedPubMedCentralCrossRef

79.

Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2014;9:004476.

80.

Wijeysundera DN, Duncan D, Nkonde-Price C, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(24):2246–64.PubMedCrossRef

81.

Gürdoğan M, Ari H, Tenekecioğlu E, et al. Predictors of atrial fibrillation recurrence in hyperthyroid and euthyroid patients. Arq Bras Cardiol. 2016;106(2):84–91.PubMedPubMedCentral

82.

Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646.PubMedCrossRef

83.

Tagami T, Yambe Y, Tanaka T, et al. Short-term effects of β-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285–90.PubMedCrossRef

84.

Trzepacz PT, Klein I, Roberts M, et al. Graves’ disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med. 1989;87(5):558–61.PubMedCrossRef

85.

Ventrella SM, Klein I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist. 1994;4(5):391–9.CrossRef

86.

Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007;120(1):10–27.PubMedCrossRef

87.

Aubert R. Diabetes in America. DIANE Publishing, 2^nd edition. NIH Publication No. 95-1468. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.

88.

Jacob S, Rett K, Henriksen EJ, et al. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta blocking agents? Am J Hypertens. 1998;11(10):1258–65.PubMedCrossRef

89.

Gottlieb S, McCarter RJ, Vogel RA, et al. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489–97.PubMedCrossRef

90.

Landray MJ, Toescu V, Kendall MJ, et al. The cardioprotective role of β-blockers in patients with diabetes mellitus. J Clin Pharm Ther. 2002;27(4):233–42.PubMedCrossRef

91.

Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997;278(1):40–3.PubMedCrossRef

92.

Hirst JA, Farmer AJ, Feakins BG, et al. Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus—a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79(5):733–43.PubMedPubMedCentralCrossRef

93.

Dominguez LJ, Barbagallo M, Jacober SJ, et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens. 1997;10:1349–55.PubMedCrossRef

94.

Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens. 2005;18:731–7.PubMedCrossRef

95.

Ladage D, Reidenbach C, Rieckeheer E, et al. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol. 2010;56(3):275–81.PubMedCrossRef

96.

Poirier L, Cléroux J, Nadeau A, et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19(8):1429–35.PubMedCrossRef

97.

Rosendorff C. Beta-blocking agents with vasodilator activity. J Hypertens. 1993;11(4):S37–40.

98.

Seguchi H, Nakamura H, Aosaki N, et al. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol. 1990;38(Suppl 2):S139–42.PubMedCrossRef

99.

Wang B, Song WH, Liu GZ, et al. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi. 2005;44(7):503–5.PubMed

100.

Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists Medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12(2):193–222.PubMed

101.

Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–87.PubMedCrossRef

102.

Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–62.PubMedCrossRef

103.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.PubMedCentralCrossRef

104.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713–20.PubMedCentralCrossRef

105.

Bell DS, Lukas MA, Holdbrook FK, et al. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin. 2006;22(2):287–96.PubMedCrossRef

106.

Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003;146(5):848–53.PubMedCrossRef

107.

Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41(9):1529–38.PubMedCrossRef

108.

Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149(1):159–67.PubMedCrossRef

109.

Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42(5):914–22.PubMedCrossRef

110.

Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.PubMedCrossRef

111.

Malmberg K, Herlitz J, Hjalmarson A, et al. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J. 1989;10(5):423–8.PubMedCrossRef

112.

Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43–50.PubMedCrossRef

113.

Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol. 1996;77(15):1273–7.PubMedCrossRef

114.

Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566.

115.

Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102:1909–14.PubMedPubMedCentralCrossRef

116.

Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;4:CD002992.

117.

Ormiston TM, Salpeter SR. Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. Heart Fail Monit. 2003;4(2):45–53.PubMed

118.

Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.PubMedCrossRef

119.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2016. http://www.ginasthma.org

120.

Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14.PubMedCrossRef

121.

Short PM, Lipworth SIW, Elder DHJ, et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.PubMedPubMedCentralCrossRef

122.

Su VY, Chang Y, Hu Y, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95(5):e2427.PubMedCentralCrossRef

123.

Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J COPD. 2015;10:515–23.CrossRef

124.

Andell P, Erlinge D, Smith JG, et al. β-Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc. 2015;4:e001611.PubMedPubMedCentralCrossRef

125.

Coiro S, Girerd N, Rossignol P, et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail. 2017;19(2):271–9. doi:10.1002/ejhf.647.PubMedCrossRef

Title: The Real Role of β-Blockers in Daily Cardiovascular Therapy
Authors: Csaba András Dézsi
Veronika Szentes
Publication date: 01-10-2017
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 5/2017
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-017-0221-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Real Role of β-Blockers in Daily Cardiovascular Therapy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy

Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice

The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin

Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine

Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications

Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page